NCT06538389 2026-04-15
High Cannabidiol Plant Extract (BRC-001) to Improve Aromatase Inhibitor-Induced Arthralgia in Women With Breast Cancer
City of Hope Medical Center
Phase 2 Suspended
Clinical Trials
10 trialsNCT05753007 2026-03-16
A Clinical Trial of a Hemp-Derived, High Cannabidiol Product for Anxiety in Glioblastoma Patients
Mclean Hospital
Phase 2 Terminated
NCT05388058 2026-01-16
Topical Cannabidiol for the Treatment of Chemotherapy-Induced Peripheral Neuropathy
Mayo Clinic
Phase 2 Completed
NCT06731894 2025-12-05
Phytocannabinoids for Reducing Chronic Chemotherapy-Induced Peripheral Neuropathy in Breast and Colon Cancer Survivors
City of Hope Medical Center
Phase 2 Recruiting
NCT03948074 2025-09-10
CAFCARS
British Columbia Cancer Agency
Phase 2 Completed
NCT04482244 2025-07-29
RCT of CBD for Anxiety in Advanced Breast Cancer
Dana-Farber Cancer Institute
Phase 2 Active not recruiting
NCT04754399 2025-05-09
Cannabidiol (CBD) for Treatment of Aromatase Inhibitor-Associated Arthralgias
University of Michigan Rogel Cancer Center
Phase 2 Completed
NCT06518434 2024-07-24
CanHep
University Medical Center Groningen
Phase 2 Recruiting
NCT04447846 2023-05-25
Novel Cognitive Treatment Targets for Epidiolex in Sturge- Weber Syndrome
Hugo W. Moser Research Institute at Kennedy Krieger, Inc.
Phase 2 Completed
NCT02255292 2014-10-02
A Study: Pure CBD as Single-agent for Solid Tumor.
Hadassah Medical Organization
Phase 2 Unknown